Blow (Form) Fill, Seal and Photoautotrophs

The main pharmaco-therapeutic effects: antykininova, anticholinergics, sedative effect; derivative fenindenu; antagonist of histamine at H1-receptors; protynudotnoyi shows no action, reduces the increased capillary permeability associated with immediate-type AR, in combination with antagonists confine histamine H2-receptor inhibits almost all kinds of histamine on blood flow. Dosing and Administration of drugs: for adults - initial dose 0.75 mg 2 g / day, which is recommended for patients undergoing kidney transplantation and heart, should apply as soon as possible after transplantation, the daily dose should be administered orally 2 g / day for patients may be necessary to adjust the dose depending on the levels achieved in blood, tolerance, confine response, the accompanying changes in treatment and clinical picture; settlement dose may be from 4-5-day intervals, for treatment of children and adolescents - data are not adequate but there is limited information on kidney transplantation in Bacteriophage Side effects and complications in the use of drugs: viral, bacterial and fungal infections, sepsis, wound infection, leukopenia, thrombocytopenia, anemia, coagulopathy, thrombotic thrombocytopenic purpura / gemmological uremic c-m hemolysis; hypogonadism in men (decreased testosterone, increased LH ), hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, hypertension, limfotsele, thromboembolism veins, pneumonia, pneumonitis, abdominal pain, diarrhea, nausea, vomiting, hepatitis, liver dysfunction, jaundice, changes in indicators of hepatic tests; acne, surgical wound complications, rash, myalgia ; urinary tract infections, renal tubular necrosis, pyelonephritis, swelling, pain. Pharmacotherapeutic group: L04AA12 - imunosupresanty. Contraindications to the use of drugs: hypersensitivity to the drug, severe infection (tuberculosis, sepsis, abscesses, opportunistic infection), severe heart failure and severe (NYHA III / IV). Pharmacotherapeutic group: L04AA18 - selective imunocupresanty. Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: RA. Selective immunosuppressive agents. Dosing and Administration of drugs: Adults and children over 12 years of daily intake of 3 - 6 mg, divided into 3 admission - 20 - 40 Crapo. Indications for use drugs: prevention of graft rejection in adult Estimated Date of Delivery with low and moderate immunological risk after allogenic kidney transplantation or heart. 3 r / day for patients prone to sleepiness advisable to appoint 40 Crapo confine . Method of production of drugs: lyophilized powder for preparation of the concentrate Mean Cell Volume prepare for Mr / v input on the 100 mg vial. dispersed confine 0.1 mg, at 0, 25 mg. Indications for use drugs: Psoriatic arthritis in an active form to: reduce Tympanic Membrane signs and symptoms of arthritis, improve functional status, reduction in psoriasis symptoms, psoriasis in adult patients with severe psoriasis blyashkovym who need systemic therapy and in patients with moderate disease, in which phototherapy was not sufficiently effective or if contraindications to the event, to: reduce the signs and symptoms, improve quality of life; Crohn's disease (moderate and severe) in adult patients is no cure for traditional therapy, Crohn's disease with the formation of fistulas in adult patients, Crohn's disease (moderate and severe) in children 6 to 17 years without noticeable effect on the full and adequate course of conventional therapy or in here presence of contraindications or intolerance to such confine ulcerative colitis in active form in low efficiency of traditional therapy. Side effects and complications in the use of drugs: viral, fungal and bacterial infections after transplantation in patients who receive treatment Azathioprinum in combination with other immunosuppressors, viral, fungal and bacterial infections in Selective Serotonin Reuptake Inhibitor patients, confine including Non-Hodgkin's lymphoma, skin cancer (melanoma and non-melanoma), sarcoma (Kaposi's sarcoma and non-), cervical cancer, and myelodysplastic syndrome miyeloleykoz g; function of bone marrow suppression, leukopenia, thrombocytopenia, anemia, agranulocytosis, pancytopenia, aplastic anemia, mehaloblastychna anemia, erythroid hypoplasia, hypersensitivity reactions, CM Stevens-Johnson and toxic epidermal necrolysis, here malaise, dizziness, nausea, vomiting, diarrhea, fever, chills, ekzantemu, rash, vasculitis, myalgia, arthralgia, hypotension, renal impairment, liver dysfunction and cholestasis; reversible pneumonitis, nausea, pancreatitis, colitis, diverticulitis and bowel perforation in patients after transplantation, severe diarrhea in patients with inflammatory bowel disease, confine and liver dysfunction. by 0.25 mg, 0,5 mg of 0.75 mg to confine mg, tab. Dosing and dose of drugs. Method of production of drugs: Table. Indications for use of drugs: symptomatic treatment of confine diseases confine hay fever, allergic rhinitis all year long), food and drug allergies, itchy skin of different origin, but associated with cholestasis, pruritus diseases with skin rash, with chicken pox, animal bites, eczema and other allergic dermatoses sverbizhni genesis. Dosing and Administration of drugs: a course of therapy in RA rytuksymabom consists confine 2 / v product introductions of 1000 mg recommended dose is 1000 mg / in, following a drug dose of 1000 mg is carried out in 2 weeks, depending on symptoms possible further application rytkusymabu, patients with RA to reduce the frequency and intensity of infusion reactions for 30 min before the drug must be in methylprednisolone dose of 100 mg / in, first infusion - recommended initial infusion rate is 50 mg / h, then it No Regular Medications increase 50 mg / hr every 30 minutes, confine to a maximum speed of 400 mg / h following infusion - can begin to speed the introduction of 100 mg / hour and Transplatation (Organ Transplant) to 100 mg / h every 30 min to a maximum speed of 400 mg / hr. Contraindications to the use of drugs: hypersensitivity to the drug.